C4 Therapeutics, Inc. (NASDAQ:CCCC) Shares Sold by Marathon Trading Investment Management LLC

Marathon Trading Investment Management LLC trimmed its holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC) by 77.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,400 shares of the company’s stock after selling 49,600 shares during the quarter. Marathon Trading Investment Management LLC’s holdings in C4 Therapeutics were worth $67,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CCCC. Commodore Capital LP purchased a new stake in C4 Therapeutics in the fourth quarter valued at approximately $21,470,000. Vanguard Group Inc. lifted its stake in C4 Therapeutics by 46.0% in the first quarter. Vanguard Group Inc. now owns 2,920,028 shares of the company’s stock valued at $23,857,000 after buying an additional 920,627 shares during the last quarter. Wasatch Advisors LP lifted its stake in C4 Therapeutics by 14.3% in the fourth quarter. Wasatch Advisors LP now owns 7,138,949 shares of the company’s stock valued at $40,335,000 after buying an additional 891,808 shares during the last quarter. Lynx1 Capital Management LP lifted its stake in C4 Therapeutics by 16.0% in the first quarter. Lynx1 Capital Management LP now owns 3,634,662 shares of the company’s stock valued at $29,695,000 after buying an additional 500,266 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in C4 Therapeutics in the second quarter valued at approximately $881,000. Hedge funds and other institutional investors own 78.81% of the company’s stock.

Wall Street Analyst Weigh In

Separately, BMO Capital Markets restated an “outperform” rating and set a $20.00 price target on shares of C4 Therapeutics in a research note on Tuesday, August 6th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, C4 Therapeutics presently has an average rating of “Hold” and an average target price of $9.29.

C4 Therapeutics Price Performance

Shares of CCCC stock opened at $6.38 on Thursday. The business’s fifty day moving average price is $6.18 and its 200 day moving average price is $6.43. C4 Therapeutics, Inc. has a 1-year low of $1.06 and a 1-year high of $11.88. The firm has a market capitalization of $438.98 million, a PE ratio of -2.69 and a beta of 3.05.

C4 Therapeutics (NASDAQ:CCCC) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.11. C4 Therapeutics had a negative return on equity of 44.60% and a negative net margin of 367.17%. The firm had revenue of $12.01 million for the quarter, compared to analyst estimates of $6.88 million. Equities research analysts expect that C4 Therapeutics, Inc. will post -1.57 earnings per share for the current fiscal year.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.